People with diabetes should avoid antibiotic gatifloxacin

CMAJ. Canadian Medical Association Journal

Volumn 174, Issue 8, 2006, Pages 1089-1090

  Kendall, Claire ^a   Wooltorton, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

CANADA; DIABETES MELLITUS; DRUG EFFECT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; SHORT SURVEY; ARTICLE; BACTERIAL INFECTION; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION; RISK FACTOR;

BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; DIABETES MELLITUS; FLUOROQUINOLONES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; RISK FACTORS;

EID: 33645953915     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060356     Document Type: Short Survey

References (3)

1. Letourneau G, Morrison H, McMorran M. Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Can Adverse Reaction Newsl 2003;13(3).
2. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Out-patient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; published 2006 Mar 1 at www.nejm.org (10.1056/NEJM0a055191).
3. Bristol-Myers Squibb Canada. Health Canada-endorsed important safety information on Tequin (gatifloxacin). Available: www.hosc.gc.ca/dhp -mps/medeff/advisories-avis/prof/2005/tequin_hpc -cps_e.html (accessed 2006 Mar 14).